Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Viridian Therapeutics Inc.
Headquarters: Boulder, CO, United States of America
Website: https://www.viridiantherape...
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Stephen Frank Mahoney, MBA
Number Of Employees: 143
Enterprise Value: $795,767,380
PE Ratio: -3.35
Exchange/Ticker 1: NASDAQ:VRDN
Exchange/Ticker 2: N/A
Latest Market Cap: $1,030,785,280
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Dec 17, 2024
Product Development
Viridian taking on Amgen in TED market
Positive data from second Phase III trial of veligrotug in thyroid eye disease; this time in chronic setting
BioCentury | Sep 13, 2024
Finance
Public Equity Report: Biotech quintet raises $1.3B+ via follow-ons
Ionis tops list of five biotechs raising at least $200M in public offerings, along with Centessa, Viridian, Relay and Xencor; plus PIPEs keep flowing
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Apr 18, 2024
Management Tracks
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury | Mar 29, 2024
Politics, Policy & Law
Small biotechs reveal reliance on Chinese CDMOs
SEC filings disclose potential negative impacts of Biosecure Act
BioCentury | Feb 17, 2024
Management Tracks
Agresta joining OnKure as CMO
Plus: Viridian hires Tousignant and an update from Ligand
BioCentury | Jan 19, 2024
Finance
Public equity roundup: Edgewise shares get lift after $240M offering
Plus offerings by Immatics, Viridion, Alector, LegoChem and more
BioCentury | Dec 20, 2023
Management Tracks
Abernethy leaving Verily for non-profit
Plus: CEO Wang leaving LianBio and more from Bicara and Hervolution, ImPact
BioCentury | Aug 31, 2023
Finance
Formulas for success from biotechs that leaped in value despite the downturn
Back to School 2023 identifies four themes among 17 companies that jumped a tier or increased their market cap over 200%
Items per page:
1 - 10 of 29